Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements Of Cash Flows (Unaudited)

v3.21.2
Consolidated Statements Of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash Flows from Operating Activities:    
Net loss $ (10,879) $ (10,687)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:    
Depreciation and amortization 281 527
Provision for bad debts (162) 1,263
Provision for sales returns 0 87
Inventory write-offs and disposals (117) 0
Amortization of discounts on lines of credit 126 123
Amortization of debt issuance costs 290 240
Patent litigation mark-to-market 190 0
Change in fair value of warrants 0 (5,850)
Issuance of restricted shares 164 0
Issuance costs for common stock warrants 0 1,640
Stock-based compensation 1,488 2,367
Gain on debt forgiveness 3,014 0
Changes in operating assets and liabilities:    
Accounts receivable (417) 4,017
Inventory (2,788) (1,597)
Prepaid expenses and other current assets 235 430
Accounts payable and accrued liabilities 705 (3,445)
Deferred revenue 292 (562)
Net cash and cash equivalents used in operating activities (13,606) (11,447)
Cash Flows from Investing Activities:    
Purchases of property, plant, and equipment (396) (78)
Net cash and cash equivalents used in investing activities (396) (78)
Cash Flows from Financing Activities:    
Proceeds from the sale of common stock 13,291 6,912
Proceeds from sale of common stock warrants 0 15,300
Proceeds from the issuance of Series F Convertible Preferred Stock 0 2,700
Payments of equity offering costs (6) (1,281)
Payment of July 2020 Warrant issuance costs 0 (1,640)
Borrowings on other long-term loans 0 3,140
Principal payment on loan 0 (700)
Borrowings on credit facility 0 3,000
Repayment of credit facility 0 (3,000)
Proceeds from the exercise of common stock warrants 16,560 46
Payment of debt issuance costs (25) (75)
Proceeds from exercise of stock options 66 0
Net cash and cash equivalents provided by financing activities 29,886 24,402
Effect of exchange rate changes (171) 181
Increase in cash, cash equivalents and restricted cash 15,713 13,058
Cash, cash equivalents and restricted cash, beginning of period 17,876 6,101
Cash, cash equivalents and restricted cash, end of period 33,589 19,159
Supplemental cash flow disclosure:    
Cash paid for interest 1,328 1,438
Cash received for interest 44 0
Cash paid for income taxes 154 21
Cash paid for operating leases 185 417
Non-cash settlement of liability 510 151
Non-cash right-of-use assets obtained in exchange for lease obligation 48 2,037
Deemed dividend on preferred stock 546 17,378
Warrants issued in connection with debt instruments $ 0 $ 67